HRP20050214B1 - Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti - Google Patents

Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti

Info

Publication number
HRP20050214B1
HRP20050214B1 HRP20050214AA HRP20050214A HRP20050214B1 HR P20050214 B1 HRP20050214 B1 HR P20050214B1 HR P20050214A A HRP20050214A A HR P20050214AA HR P20050214 A HRP20050214 A HR P20050214A HR P20050214 B1 HRP20050214 B1 HR P20050214B1
Authority
HR
Croatia
Prior art keywords
oral solid
solid drug
crystal
same
dysuria
Prior art date
Application number
HRP20050214AA
Other languages
English (en)
Croatian (hr)
Inventor
Eiji Tsuru
Michio Toda
Kazuma Hirata
Original Assignee
Kissei Pharmaceutical Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31973150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050214(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Co.Ltd. filed Critical Kissei Pharmaceutical Co.Ltd.
Publication of HRP20050214A2 publication Critical patent/HRP20050214A2/hr
Publication of HRP20050214B1 publication Critical patent/HRP20050214B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20050214AA 2002-09-06 2003-09-05 Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti HRP20050214B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002262157 2002-09-06
PCT/JP2003/011345 WO2004022538A1 (ja) 2002-09-06 2003-09-05 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬

Publications (2)

Publication Number Publication Date
HRP20050214A2 HRP20050214A2 (en) 2006-05-31
HRP20050214B1 true HRP20050214B1 (hr) 2013-09-30

Family

ID=31973150

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050214AA HRP20050214B1 (hr) 2002-09-06 2003-09-05 Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti

Country Status (23)

Country Link
US (1) US20060142374A1 (enExample)
EP (1) EP1541554B1 (enExample)
JP (1) JP4532274B2 (enExample)
KR (1) KR100670592B1 (enExample)
CN (1) CN1321111C (enExample)
AT (1) ATE416159T1 (enExample)
AU (1) AU2003264385B2 (enExample)
BR (1) BR0314338A (enExample)
CA (1) CA2496780C (enExample)
DE (1) DE60325074D1 (enExample)
ES (1) ES2316858T3 (enExample)
HR (1) HRP20050214B1 (enExample)
IL (1) IL167168A (enExample)
IS (1) IS2640B (enExample)
MX (1) MXPA05002549A (enExample)
NO (2) NO329855B1 (enExample)
NZ (1) NZ538598A (enExample)
PL (1) PL375701A1 (enExample)
RU (1) RU2347774C2 (enExample)
TW (1) TW200407126A (enExample)
UA (1) UA78854C2 (enExample)
WO (1) WO2004022538A1 (enExample)
ZA (1) ZA200501884B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20050544B1 (hr) * 2002-12-16 2017-12-01 Kissei Pharmaceutical Co., Ltd. Čvrsti oblik za oralnu upotrebu
CA2557758C (en) 2004-03-05 2013-09-10 Kissei Pharmaceutical Co., Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
JPWO2006038611A1 (ja) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
ATE535242T1 (de) * 2004-10-06 2011-12-15 Kissei Pharmaceutical Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
HRP20130622T1 (en) * 2005-02-17 2013-08-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
RS52183B (sr) * 2006-12-14 2012-10-31 Teva Pharmaceutical Industries, Ltd. Kristalna čvrsta baza razagilina
EP2125717B1 (en) * 2007-02-26 2013-07-03 Concert Pharmaceuticals Inc. Deuterated derivatives of silodosin as alpha ia-adrenoreceptor antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
WO2012010669A2 (de) 2010-07-23 2012-01-26 Ratiopharm Gmbh Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
WO2012014186A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
CN102010359B (zh) * 2010-09-10 2013-01-23 北京阳光诺和药物研究有限公司 β晶型西洛多辛的制备方法
WO2012077138A1 (en) 2010-12-09 2012-06-14 Panacea Biotec Limited Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
EP2474529B1 (en) 2010-12-23 2014-05-14 Sandoz AG Crystalline forms of an active pharmaceutical ingredient
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
JP6392207B2 (ja) * 2013-03-26 2018-09-19 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
WO2015015512A2 (en) * 2013-07-29 2015-02-05 Ind-Swift Laboratories Limited Process for the preparation of silodosin and its gamma form
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
WO2015119057A1 (ja) 2014-02-06 2015-08-13 宇部興産株式会社 インドリン化合物の製造方法
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
KR101673160B1 (ko) 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법
JP2016147811A (ja) * 2015-02-10 2016-08-18 ダイト株式会社 シロドシンγ型結晶の製造方法
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
KR101733084B1 (ko) 2016-07-27 2017-05-08 (주)다산메디켐 실로도신의 결정형의 제조방법
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN107903201B (zh) * 2017-12-27 2020-09-25 浙江天宇药业股份有限公司 一种β晶型西洛多辛的制备方法
CN111410626B (zh) * 2019-01-04 2022-11-04 上海汇伦医药股份有限公司 赛洛多辛α-晶型的制备方法
CN109824569B (zh) * 2019-04-04 2022-09-20 重庆医药高等专科学校 一种西罗多辛晶型i及其制备方法
WO2020237643A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛α-晶型的制备方法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07330726A (ja) * 1994-06-01 1995-12-19 Kissei Pharmaceut Co Ltd インドール誘導体
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
JP2000247998A (ja) * 1999-02-26 2000-09-12 Kissei Pharmaceut Co Ltd α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP2002265444A (ja) * 2001-03-08 2002-09-18 Kissei Pharmaceut Co Ltd １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319551T2 (de) * 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
JP4342101B2 (ja) * 1998-02-27 2009-10-14 キッセイ薬品工業株式会社 インドール誘導体および当該誘導体を含有する医薬品組成物
AU3011299A (en) * 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
EP1806340B1 (en) * 2004-10-27 2011-05-04 Kissei Pharmaceutical Co., Ltd. Indoline compound and process for producing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07330726A (ja) * 1994-06-01 1995-12-19 Kissei Pharmaceut Co Ltd インドール誘導体
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
JP2000247998A (ja) * 1999-02-26 2000-09-12 Kissei Pharmaceut Co Ltd α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP2002265444A (ja) * 2001-03-08 2002-09-18 Kissei Pharmaceut Co Ltd １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法

Also Published As

Publication number Publication date
IS2640B (is) 2010-06-15
KR20050057181A (ko) 2005-06-16
NO2011011I1 (no) 2011-07-25
HK1084396A1 (en) 2006-07-28
IS7785A (is) 2005-04-05
JP4532274B2 (ja) 2010-08-25
AU2003264385A1 (en) 2004-03-29
ATE416159T1 (de) 2008-12-15
ES2316858T3 (es) 2009-04-16
CN1694867A (zh) 2005-11-09
CA2496780A1 (en) 2004-03-18
MXPA05002549A (es) 2005-06-03
RU2005109930A (ru) 2006-01-20
WO2004022538A1 (ja) 2004-03-18
TW200407126A (en) 2004-05-16
KR100670592B1 (ko) 2007-01-17
NO2011011I2 (enExample) 2012-10-01
RU2347774C2 (ru) 2009-02-27
EP1541554A1 (en) 2005-06-15
HRP20050214A2 (en) 2006-05-31
US20060142374A1 (en) 2006-06-29
EP1541554A4 (en) 2006-11-08
TWI305148B (enExample) 2009-01-11
JPWO2004022538A1 (ja) 2005-12-22
IL167168A (en) 2010-11-30
NZ538598A (en) 2007-08-31
DE60325074D1 (de) 2009-01-15
CN1321111C (zh) 2007-06-13
NO20051709L (no) 2005-06-06
PL375701A1 (en) 2005-12-12
ZA200501884B (en) 2006-05-31
BR0314338A (pt) 2005-07-05
AU2003264385B2 (en) 2009-12-17
NO329855B1 (no) 2011-01-10
EP1541554B1 (en) 2008-12-03
CA2496780C (en) 2011-03-15
UA78854C2 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
PL375701A1 (en) Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
MY139571A (en) Indolyl derivatives as liver-x-receptor modulators
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
UA74391C2 (uk) Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
CA2415438A1 (fr) Forme cristalline .alpha. du sel de tert-butylamine du perindopril
SE0402762D0 (sv) Indazole sulphonamide derivatives
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CO5560555A2 (es) Cristales de derivado de hidroxinorefedrina
EP1284265A4 (en) BENZOTHIOPHENE DERIVATIVES AND MEDICINAL USE THEREOF
GB9108629D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
MY121170A (en) Polymorphic salt of an anti-migrain drug.
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE180405T1 (de) Arzneimittel enthaltend einen quisqualat-rezeptor-antagonisten und einen dopamin-agonisten zur behandlung des morbus parkinson
DE69318715D1 (de) Pharmakologisch aktive alpha-(tertiär-aminoethyl)-phenylmethanol-derivate
IL169294A (en) Atropisomers of 3-substituted 4-arylquinolin-2-one derivatives and pharmaceutical compositions containing the same
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190809

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200819

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210830

Year of fee payment: 19

PBON Lapse due to non-payment of renewal fee

Effective date: 20220905